1 Biotech Stock to Buy in 2025, and 1 to Avoid

Viking Therapeutics (NASDAQ: VKTX) and Novavax (NASDAQ: NVAX) were two of the big winners in the biotech industry last year. Both companies saw their shares rise significantly; the former had exciting clinical progress, while the latter signed a lucrative deal with a biotech giant that had Wall Street cheering.Are these stocks worth buying in 2025 after their strong performance last year? My view is that only one of them looks attractive, while the other isn't worth the trouble. Here's why.Weight-loss drugs like Wegovy and Zepbound are proving incredibly lucrative, and analysts project this field will grow by leaps and bounds through the end of the decade. Viking Therapeutics is looking to carve out a niche thanks to VK2735, a potential anti-obesity therapy that aced phase 2 studies last year.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool